[SCHEDULE 13G/A] EyePoint Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Schedule 13G/A (Amendment 1) filed for EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) discloses that Federated Hermes, Inc. and related reporting persons—Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue—collectively hold 4,599,450 shares of EyePoint common stock, representing 6.68 % of the outstanding class as of 30 June 2025.

The filing is made under Rule 13d-1(b) indicating a passive investment. Federated Hermes has sole voting and dispositive power over all reported shares; the individual Donahues share voting/dispositive power through the Trust. No other parties share control, and the group certifies the stake was acquired in the ordinary course of business with no intent to influence control of the issuer.

Key details for investors:

• Ownership threshold: Stake exceeds the 5 % reporting trigger, signalling meaningful institutional involvement.
• Aggregation structure: Shares are held via a Pennsylvania-based trust controlled by Federated Hermes executives, consolidating voting power.
• Certification: Reporting persons affirm the investment is non-activist and purely passive.

No financial performance data, purchase price or transaction timing beyond the “Date of Event” are provided.

Positive

• Federated Hermes, Inc. holds 6.68 % of EyePoint’s outstanding shares, indicating meaningful institutional interest and potential confidence in the company’s prospects.

Negative

• None.

Insights

Financial Analyst

TL;DR – Federated Hermes now owns 6.68 % of EYPT, reflecting passive but notable institutional support.

The amendment shows Federated Hermes and related Donahue family trusts have accumulated 4.6 million shares, signalling increasing institutional confidence in EyePoint’s ophthalmology pipeline. While a 13G filing is passive—so no governance pressure—crossing the 5 % threshold can improve liquidity and visibility among other institutions. The single-holder concentration also means any future changes (buying or selling) could move the stock. Absent price or cost data, the filing is informational rather than catalytic, but investors may view sustained ownership by a respected asset manager as a modest positive.

Corporate Governance Specialist

TL;DR – New 6.68 % stake is passive; no immediate governance impact expected.

Because the report is on Schedule 13G rather than 13D, Federated Hermes disclaims any intent to influence control. The voting and dispositive powers rest with the asset manager, concentrated in a single trust structure. This reduces the likelihood of shareholder proposals or board challenges arising from this group. The filing mainly informs other shareholders of a significant but non-activist bloc, so governance dynamics remain unchanged.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

EYEPOINT PHARMACEUTICALS, INC.

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

30233G209

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 30233G209

1

Names of Reporting Persons

Federated Hermes, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,599,450.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,599,450.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,599,450.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.68 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 30233G209

1

Names of Reporting Persons

Voting Shares Irrevocable Trust

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,599,450.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,599,450.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,599,450.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.68 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 30233G209

1

Names of Reporting Persons

Thomas R. Donahue

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,599,450.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,599,450.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,599,450.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.68 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 30233G209

1

Names of Reporting Persons

Ann C. Donahue

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,599,450.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,599,450.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,599,450.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.68 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 30233G209

1

Names of Reporting Persons

J. Christopher Donahue

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,599,450.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,599,450.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,599,450.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.68 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: EYEPOINT PHARMACEUTICALS, INC.
(b)	Address of issuer's principal executive offices: 480 Pleasant Street, Suite C400, Watertown, MA 02472
Item 2.
(a)	Name of person filing: Federated Hermes, Inc.
(b)	Address or principal business office or, if none, residence: 1001 Liberty Avenue, Pittsburgh, PA 15222-3779
(c)	Citizenship: Pennsylvania
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 30233G209
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,599,450
(b)	Percent of class: 6.68 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4,599,450
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4,599,450
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit "1" Attached
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Federated Hermes, Inc.

Signature:	/s/J. Christopher Donahue
Name/Title:	J. Christopher Donahue, as President of Federated Hermes, Inc.
Date:	07/07/2025

Voting Shares Irrevocable Trust

Signature:	/s/Thomas R. Donahue
Name/Title:	Thomas R. Donahue, as Trustee of Voting Shares Irrevocable Trust
Date:	07/07/2025

Signature:	/s/Ann C. Donahue
Name/Title:	Ann C. Donahue, as Trustee of Voting Shares Irrevocable Trust
Date:	07/07/2025

Signature:	/s/J. Christopher Donahue
Name/Title:	J. Christopher Donahue, as Trustee of Voting Shares Irrevocable Trust
Date:	07/07/2025

Thomas R. Donahue

Signature:	/s/Thomas R. Donahue
Name/Title:	Thomas R. Donahue
Date:	07/07/2025

Ann C. Donahue

Signature:	/s/Ann C. Donahue
Name/Title:	Ann C. Donahue
Date:	07/07/2025

J. Christopher Donahue

Signature:	/s/J. Christopher Donahue
Name/Title:	J. Christopher Donahue
Date:	07/07/2025

Comments accompanying signature: SEE EXHIBITS 2 AND 3 ATTACHED Exhibit Information Exhibit 1 ITEM 3 CLASSIFICATION OF REPORTING PERSONS EXHIBIT 2 AGREEMENT FOR JOINT FILING OF SCHEDULE 13G EXHIBIT 3 POWER OF ATTORNEY

FAQ

How many EyePoint (EYPT) shares does Federated Hermes now own?

The group reports ownership of 4,599,450 common shares.

What percentage of EyePoint’s outstanding stock is represented by this stake?

The filing states the stake equals 6.68 % of the class.

Is Federated Hermes seeking control of EyePoint Pharmaceuticals?

No. The Schedule 13G filing and certification confirm the shares are held for passive investment purposes only.

Who has voting and dispositive power over the shares?

Federated Hermes has sole voting and dispositive power over all reported shares.

When did the ownership position become reportable?

The date of event triggering this amendment is 30 June 2025.